Andrew Musgrave Host
00:05
Welcome to another episode of ASX Briefs, and today we welcome back Tom Spurling, the Managing Director of Nova Eye Medical Limited, trading under the ticker code EYE. Nova Eye Medical continues to lead innovation in ophthalmic treatment technologies, achieving significant milestones in its journey to revolutionise glaucoma care. Tom, thanks for joining me today and welcome back to the podcast.
Tom Spurling Guest
00:28
Thanks for having me back. It's really good to be here. I appreciate the interest.
Andrew Musgrave Host
00:33
Okay, now let's start with the headline numbers. Nova Eye recently reported a robust 44% growth in global sales over the trailing 12 months to October 2024. So, can you break down the key drivers behind this performance?
Tom Spurling Guest
00:47
Yeah, for sure. Look, our growth is a result of well, it's particularly focused in the United States, but it's across multiple markets. In the US we've seen 55% growth driven by a strong uptake of our iTrack™ Advanced Canaloplasty device, which continues to gain fraction among surgeons. Our efforts to expand in other territories, like China, have also started to yield results, and the product innovation, the marketing effort and getting the sales team on the ground to meet that demand has been the recipe we've applied.
Andrew Musgrave Host
01:24
And the iTrack™ Advance seems to be at the centre of this growth, so can you share more about its impact and how it differentiates Nova Eye in the glaucoma treatment market?
Tom Spurling Guest
01:35
Yes. Well, iTrack™ leaves nothing behind. It is stent-free, tissue-preserving, offering an effective alternative to traditional glaucoma treatments that involve tearing tissue or leaving a stent behind. It was approved in 2023, and we simplified the procedure for surgeons. We made it easier for a wider population of ophthalmic surgeons to use. This idea, that it preserves the eye's natural pathways, is the key differentiator from the other devices. Keeping in mind, glaucoma is a failure of plumbing and by reinvigorating the natural outflow pathways, we clear blockages. And clearing blockages early in the disease state is the growing trend in intervening with glaucoma in a minimally invasive way, early in the disease state.
Andrew Musgrave Host
02:36
Your AGM presentation highlighted a rebound in October 2024 after temporary supply chain challenges. Can you provide more context on this?
Tom Spurling Guest
02:48
Yeah, we manufacture a very unique, very small catheter and we had a disruption to part of the process that bring those together during August and September and that slowed our growth temporarily. Meeting demand, or you know people will say, oh, meeting demand. You always have supply chain challenges, Tom. It was still annoying, we had them, but we got ourselves organized. We've got enough people. We resolved the issues properly and October we resumed sales flat out. It was a great month. We're very excited by it.
Andrew Musgrave Host
03:22
And international markets like China and Europe also saw growth. So, what's driving success in these regions?
Tom Spurling Guest
03:29
So, in China we made a concerted effort to restructure how we planned our sales and engaged with our distributor and as a result, we've had a more consistent flow of orders. As a result, we've had a more consistent flow of orders. In Europe, surgeon adoption continues to grow because we did invest in a new person in the area new people in the area and we're getting in front of those doctors. We've had a dedicated band of followers of German doctors but getting in front of those, we've increased their usage, and we had a great presentation with lots of papers at the European Society of Cataract and Refractive Surgeons in September where our experiences with iTrack™ were presented, and that really has driven some interest for us.
Andrew Musgrave Host
04:23
And what are the strategic priorities for the company as you look ahead to FY25?
Tom Spurling Guest
04:28
Yep, our top priority is making sure that we continue to have growth in the US. We have a relatively new team of sorry, we've recently hired when I say recently, a few months ago hired new sales reps, and those sales reps are just hitting their straps now. We also are seeing our investments in China and Germany coming to fruition, and so our main goal, we believe during FY25, our glaucoma division, which comprises most of our business, will move to a break-even position, and we're very excited about that in terms of financial break-even.
Andrew MusgraveHost
05:11
And now if we look at the market opportunities, the global glaucoma surgical device market presents a substantial opportunity, particularly with 1 million cataract patients having concurrent glaucoma annually in the US. So how does the company plan to capture a larger share of this growing market?
Tom Spurling Guest
05:30
So, it is about the coexistence of glaucoma in one million cataract patients is a significant market opportunity.
It's about doctors being able to say to patients I'm going to fix your vision with a new lens, but at the same time I want to get you off drops or reduce the number of drops you have to take. It's a compelling proposition and all in the same surgery and that procedure, that opportunity, is all about getting feet on the ground to get in front of those surgeons to explain what we can do. Our natural, stent-free, tissue-preserving, get you off drops and, should your glaucoma deteriorate, we've still got options in the future because we haven't upset the natural system. It's a very large opportunity and we're very excited by it. Our opportunity in order to get in front of these doctors. I mean, there's a little recipe I like to say we have the market brand awareness, getting doctors to understand who we are, getting the surgeons, key opinion leaders, to talk about us on the podium, and then we lay over the top of that a band of experienced salespeople to go out and get those orders. That's what we're doing and we're excited about it.
Andrew Musgrave Host
07:02
And one final question Tom, how does the company's valuation compare to its peers and what message would you like to share with the current or potential investors?
Tom Spurling Guest
07:10
Sure, well, as a CEO of a business, I'm never happy with our share price. That's common. So currently our multiple revenue to market cap multiple is about 1.3. Our peers, one peer is trading at about 20 times and the other peer is trading at about 4 times. So, we see that and they're losing a lot, and so we are on our major competitor we're gaining market share. So, we think we have a more valuable revenue proposition, and it makes a good value proposition for potential investors.
Andrew Musgrave Host
07:57
All right, Tom. Well, thanks for your time today. It's been great to catch up again and get an update on where the company is at, and we look forward to further updates in the upcoming months.
Tom Spurling Guest
08:05
Thanks, Andrew, thanks very much.
Andrew Musgrave Host
08:08
That concludes this episode of ASX Briefs. Don't forget to subscribe and we look forward to catching you on our next episode.